ABSTRACT
Endometrial cancer is an emerging disease with an increase in prevalence of aggressive histotypes in recent years. In the present study potential histopathological and immunohistochemical prognostic markers are investigated
Consecutive cases of high grade non-endometrioid carcinoma (HG-NEC) of the endometrium were considered. Each surgical specimen has been routinely processed, the most representative block has been selected for immunohistochemistry and tested for ER, PR, ki67, p53, E-cadherin, β-catenin, Bcl-2 and cyclin D1. For each immunomarker the percentage of positive tumor cells were evaluated (%) and dichotomized as low and high according to the distribution in the study population. Follow-up was collected for disease-free survival (DFS) and overall survival (OS).
33 cases were eligible: 19 resulted FIGO I-II, 14 resulted FIGO III-IV. 12 patients suffered a recurrent disease (mean follow-up 24.6 months); 8 patients died of the disease (mean follow-up 26.6 months).
Women with recurrent disease demonstrated a significant higher bcl2% (35.84±30.96% vs 8.09±11.56% p=0.0032) while DOD patients had higher ki67% (75±13.09% vs 58.6±19.97% p=0.033) and bcl2% of border significance (34.37±34.99% vs 13±17.97% p=0.078).
As expected FIGO III-IV had a worse DFS (HR=3.34; 95%CI:1.1-10.99; p=0.034) and OS (HR=5.19; 95%CI: 1.27-21.14 p= 0.0217). Bcl2-high patients (bcl2>10%) demonstrated a significant worse DFS (HR=9.11; 95%CI: 2.6-32.4; p=0.0006) and OS (HR=7.63; 95%CI:1.7-34; p=0.0084); also PR low patients (PR≤10%) had a significant worse DFS (HR=3.74; 95%CI:1.2-11.9; p=0,02).
HG-NEC represent an heterogeneous group of endometrial aggressive neoplasms with a worrisome prognosis often at an advanced stage at presentation. Bcl2 and PR may represent promising markers to identify a sub-group of patients having an even worse prognosis requiring a careful and close follow-up.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Retrospective Study
Funding Statement
Funding: the current work was granted by University of Genoa Research Funds (FRA)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Liguria Regional Ethic Committee (Prot. Pubb.HG-NECs_Vellone2021)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵°GYN DMT, a multidisciplinary team of specialist physicians of Ospedale Policlinico San Martino, Genoa, involved in diagnosis and treatment of gynecologic malignancies composed by Serafina Mammoliti (Oncology), Cinzia Caroti (Oncology Clinic), Sergio Costantini (Obstetrics & Gynecology Clinic), Angelo Cagnacci (Obstetrics & Gynecology Clinic), Melita Moioli (Obstetrics & Gynecology Clinic), Maria Grazia Centurioni (Obstetrics & Gynecology), Franco Alessandri (Obstetrics & Gynecology), Luca Dogliotti (Radiology), Maurizio Cosso (Radiology), Michela Marcenaro (Radiation Oncology), Flavio Giannelli (Radiation Oncology), Stefano Di Domenico (General Surgery) and Franco De Cian (General Surgery)
DECLARATIONS
Funding: the current work was granted by University of Genoa Research Funds (FRA)
Conflicts of interest/Competing interests: no conflicts of interest Availability of data and material (data transparency): the presented dated are available to asking scholars
Data Availability
Availability of data and material (data transparency): the presented dated are available to asking scholars
